12 month results of safety, efficacy, and stability of advanced surface laser ablation (TransPRK) in high myopia
Session Details
Session Title: Surface Photoablation/PRK
Session Date/Time: Tuesday 25/09/2018 | 14:00-16:00
Paper Time: 15:44
Venue: Room A3, Podium 2
First Author: : A.Zafar GREECE
Co Author(s): : I. Aslanides V. Selimis
Abstract Details
Purpose:
We report 12 months results of All Surface Laser Ablation (ASLA/TransPRK) in patients with high myopia (SE≥6.00D)
Setting:
Emmetropia Mediterranean Eye Institute, Heraklion, Crete, Greece
Methods:
One hundred ninety-nine (199) eyes of one hundred fifteen (115) myopic patients with a range of -6.00 up to-11.875 Dioptres (D) (mean -7.58 D) underwent ASLA (All Surface Laser Ablation) treatment using the Amaris 750S laser platform (SCHWIND eye-tech-solutions, Kleinhostheim Germany) along with MMC and/or prophylactic corneal cross-linking (CXL). The results regarding UDVA, CDVA, refraction and corneal haze are presented at 1 month, 3 months, 6 months and 12 months postoperatively for the evaluation of this technique’s efficacy, safety and stability.
Results:
The ASLA technique proved to be safe with >90% of the patients having the same or even better CDVA post-operatively than before the treatment. About 90% of the patients had a postoperative refraction ranging from -0.50D to +0.50D and this number goes up to 95% for refractions ranging from -1.00D to +1.00D. Regarding post-operative astigmatism 91% of patients had up to -0.50D of cylinder (82% up to -0.25D). The haze was minimal at all times (maximum average score 0.16 in the Fantes scale) and never significantly affected the visual acuity of the patients.
Conclusions:
ASLA seems to be a very effective technique for the treatment of high myopia (SE≥6.00D) offering predictable results. In the same time, it proved to be efficacious as about the same percentage of patients had a post-operative UDVA of 20/20 or better. The refraction was stable at all major post-operative time points while the corneal haze score was insignificant.
Financial Disclosure:
-